These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 16938288)

  • 21. Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.
    Kusunoki H; Taniyama Y; Azuma J; Iekushi K; Sanada F; Otsu R; Iwabayashi M; Okayama K; Rakugi H; Morishita R
    Hypertension; 2012 Feb; 59(2):308-16. PubMed ID: 22252391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action.
    Ishiguro H; Ishiguro Y; Kubota Y; Uemura H
    Prostate; 2007 Jun; 67(9):924-32. PubMed ID: 17440964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro.
    Ren L; Liu N; Zhi H; Li Y; Li Y; Tang R; Sheng Z
    Cardiovasc Diabetol; 2011 Jan; 10():10. PubMed ID: 21269478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TGF-β1 downregulates AT1 receptor expression via PKC-δ-mediated Sp1 dissociation from KLF4 and Smad-mediated PPAR-γ association with KLF4.
    Zhang XH; Zheng B; Gu C; Fu JR; Wen JK
    Arterioscler Thromb Vasc Biol; 2012 Apr; 32(4):1015-23. PubMed ID: 22282354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Telmisartan exerts antiatherosclerotic effects by activating peroxisome proliferator-activated receptor-γ in macrophages.
    Matsumura T; Kinoshita H; Ishii N; Fukuda K; Motoshima H; Senokuchi T; Taketa K; Kawasaki S; Nishimaki-Mogami T; Kawada T; Nishikawa T; Araki E
    Arterioscler Thromb Vasc Biol; 2011 Jun; 31(6):1268-75. PubMed ID: 21474824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor γ among clinically used angiotensin II receptor blockers: drug-target interaction analyses.
    Kakuta H; Kurosaki E; Niimi T; Gato K; Kawasaki Y; Suwa A; Honbou K; Yamaguchi T; Okumura H; Sanagi M; Tomura Y; Orita M; Yonemoto T; Masuzaki H
    J Pharmacol Exp Ther; 2014 Apr; 349(1):10-20. PubMed ID: 24424487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deletion of angiotensin II type I receptor reduces hepatic steatosis.
    Nabeshima Y; Tazuma S; Kanno K; Hyogo H; Chayama K
    J Hepatol; 2009 Jun; 50(6):1226-35. PubMed ID: 19395110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-gamma activation.
    Yamamoto K; Ohishi M; Ho C; Kurtz TW; Rakugi H
    Hypertension; 2009 Dec; 54(6):1353-9. PubMed ID: 19822796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AT1-receptor-deficiency induced atheroprotection in diabetic mice is partially mediated via PPARγ.
    Tiyerili V; Becher UM; Aksoy A; Lütjohann D; Wassmann S; Nickenig G; Mueller CF
    Cardiovasc Diabetol; 2013 Feb; 12():30. PubMed ID: 23374104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice.
    Min LJ; Mogi M; Shudou M; Jing F; Tsukuda K; Ohshima K; Iwanami J; Horiuchi M
    Hypertension; 2012 May; 59(5):1079-88. PubMed ID: 22454480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation.
    Matsui T; Yamagishi S; Ueda S; Nakamura K; Imaizumi T; Takeuchi M; Inoue H
    J Int Med Res; 2007; 35(4):482-9. PubMed ID: 17697525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Telmisartan, a dual ARB/partial PPAR-γ agonist, protects myocardium from ischaemic reperfusion injury in experimental diabetes.
    Goyal SN; Bharti S; Bhatia J; Nag TC; Ray R; Arya DS
    Diabetes Obes Metab; 2011 Jun; 13(6):533-41. PubMed ID: 21320264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Telmisartan prevents the progression of renal injury in daunorubicin rats with the alteration of angiotensin II and endothelin-1 receptor expression associated with its PPAR-γ agonist actions.
    Arozal W; Watanabe K; Veeraveedu PT; Ma M; Thandavarayan RA; Sukumaran V; Suzuki K; Kodama M; Aizawa Y
    Toxicology; 2011 Jan; 279(1-3):91-9. PubMed ID: 20888384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-γ-dependent activity.
    Toyama K; Nakamura T; Kataoka K; Yasuda O; Fukuda M; Tokutomi Y; Dong YF; Ogawa H; Kim-Mitsuyama S
    Biochem Biophys Res Commun; 2011 Jul; 410(3):508-13. PubMed ID: 21679694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia.
    Nagashima A; Watanabe R; Ogawa M; Suzuki J; Masumura M; Hishikari K; Shimizu T; Takayama K; Hirata Y; Nagai R; Isobe M
    J Cardiovasc Pharmacol; 2012 Aug; 60(2):158-64. PubMed ID: 22561360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Valsartan and telmisartan abrogate angiotensin II-induced downregulation of ABCA1 expression via AT1 receptor, rather than AT2 receptor or PPARγ activation.
    Chen HY; Xu Z; Chen LF; Wang W; Fang Q; Yan XW
    J Cardiovasc Pharmacol; 2012 Jun; 59(6):570-5. PubMed ID: 22392065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Telmisartan increases localization of glucose transporter 4 to the plasma membrane and increases glucose uptake via peroxisome proliferator-activated receptor γ in 3T3-L1 adipocytes.
    Furukawa H; Mawatari K; Koyama K; Yasui S; Morizumi R; Shimohata T; Harada N; Takahashi A; Nakaya Y
    Eur J Pharmacol; 2011 Jun; 660(2-3):485-91. PubMed ID: 21514293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice.
    Iwanami J; Mogi M; Tsukuda K; Min LJ; Sakata A; Jing F; Iwai M; Horiuchi M
    J Hypertens; 2010 Aug; 28(8):1730-7. PubMed ID: 20498620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats.
    Kobayashi N; Ohno T; Yoshida K; Fukushima H; Mamada Y; Nomura M; Hirata H; Machida Y; Shinoda M; Suzuki N; Matsuoka H
    Am J Hypertens; 2008 May; 21(5):576-81. PubMed ID: 18437150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment with telmisartan attenuates graft arteriosclerosis in murine cardiac allografts.
    Kosuge H; Ishihara T; Haraguchi G; Maejima Y; Okada H; Saiki H; Suzuki J; Isobe M
    J Heart Lung Transplant; 2010 May; 29(5):562-7. PubMed ID: 20044279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.